Lipoprotein(a): Laboratory Testing and Clinical Use


Tuesday, July 25
6 – 7 p.m.
Location TBD
Sponsored by Helena


Lipoprotein(a) [Lp(a)] is a member of the ApoB family of lipoproteins, which bears independent risk of atherosclerotic cardiovascular events. Approximately 20% of individuals have elevations in Lp(a); most of these patients are unaware of the risk because screening or Lp(a) is not routinely implemented in clinical practice. Here we will discuss these aspects, standard and esoteric testing for Lp(a), and how the complexity of the molecular structure of this biomarker influences measurement and challenges clinical laboratory practice. Further, we will explain how those results can guide clinical management of patients at risk and influence cascade family testing strategies.


Joseph P. McConnell, PhD, DABCC, MT(ASCP)
Consultant, Salveo Diagnostics

Robert S. Galen, MD, MPH
Professor Emeritus
University of Georgia College of Public Health


Leslie J. Donato, PhD
Co-Director- Hospital Clinical Laboratory, division of Critical Care Laboratory Devices
Mayo Clinic

Vlad C. Vasile, MD, PhD
Assistant Professor Laboratory Medicine and Pathology; Consultant, Division of Preventive Cardiology
Mayo Clinic